NLTX
$11.31
Neoleukin Therapeutics
$.10
.89%
NLTX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.21)
Revenue:  $0.00 Mil
Wednesday
Nov 11
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NLTX reports earnings?
Beat
Meet
Miss

Where is NLTX's stock price going from here?
Up
Flat
Down
Stock chart of NLTX
Analysts
Summary of analysts' recommendations for NLTX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in creating next generation immunotherapies using de novo protein design technology. The company's product candidate consists of NL-201 which is in clinical stage. Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals Inc., is based in Seattle, United States.